By Chris Wack
Protagonist Therapeutics shares were up 28% to $49.25 after the company reported positive topline results from a Phase 2b study of icotrokinra, conducted by partner Johnson & Johnson.
The biopharmaceutical company said icotrokinra is a targeted oral peptide that selectively blocks the IL-23 receptor in adults with moderately to severely active ulcerative colitis.
Protagonist said the study met its primary endpoint of clinical response in all icotrokinra dose groups evaluated. The study also demonstrated clinically meaningful differences versus placebo in key secondary endpoints of clinical remission, symptomatic remission and endoscopic improvement at week 12.
Icotrokinra had a response rate of 63.5% for patients treated with the highest dose at week 12, versus 27% for placebo. Clinical remission and response rates continued to improve through week 28.
Icotrokinra was well tolerated with the proportions of participants reporting one or more adverse events being similar between the icotrokinra dose groups and the placebo group.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
March 10, 2025 09:44 ET (13:44 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.